Davidson M, Wagner AD, Kouvelakis K, et al. - Researchers conducted the largest pooled analysis of gender effect on treatment and outcome in advanced oesophagogastric cancer. They pooled the data for patients with advanced oesophagogastric cancer randomized to comparable first-line chemotherapy regimens within four United Kingdom prospective trials, and compared the key demographic and outcome measures between males and females. Among 1,654 included patients, 1,328 (80.3%) were males and 326 (19.7%) were females. The analysis revealed higher rates of clinically significant toxicities among females. In addition, a significantly higher incidence of serious adverse events on treatment and comparatively less cycles of chemotherapy overall were reported among females than males. These findings seem to have implications in providing patient education and clinical practice.